Results 261 to 270 of about 114,609 (356)

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Open-label placebo for non-specific pain in the emergency department (OLP EM): study protocol for a mixed-method randomised control feasibility study in Switzerland. [PDF]

BMJ Open
Degen B, Szczesna A, Nickel CH, Bingisser R, Gaab J, Minotti B.   +5 more
europepmc   +1 more source

Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. [PDF]

, 1981
V. Hossmann, Garret A. FitzGerald, C T Dollery   +2 more
openalex   +1 more source

Notes from the field: The Inflation Reduction Act and Enbrel

Arthritis &Rheumatology, Accepted Article.
Charles L Bennett, Jason B Gibbons, Chadi Nabhan, Kenneth R Carson, June M McKoy, Kevin B Knopf, Gerald Anderson   +6 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

100,000 lumens to treat seasonal affective disorder: A proof of concept RCT of Bright, whole‐ROom, All‐Day (BROAD) light therapy

Depression and Anxiety, Volume 39, Issue 12, Page 760-769, December 2022., 2022
Abstract Background Seasonal affective disorder (SAD) is common and debilitating. The standard of care includes light therapy provided by a light box; however, this treatment is restrictive and only moderately effective. Advances in LED technology enable lighting solutions that emit vastly more light than traditional light boxes.
Julia F. Sandkühler, Sarah Brochhagen, Paul Rohde, Rosa C. Muscheidt, Teja W. Grömer, Helge Müller, Jan M. Brauner   +6 more
wiley   +1 more source

Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. [PDF]

, 1982
Samuel J. Brodsky, Sally S. Cutler, D A Weiner, Carolyn H. McCabe, Thomas J. Ryan, M. D. Klein   +5 more
openalex   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

A double-crossover trial comparing the effects of topical carteolol and placebo on intraocular pressure. [PDF]

, 1988
G. R. Duff, P. A. Graham
openalex   +1 more source

Placebo Effects: Neurological Mechanisms Inducing Physiological, Organic, and Belief Responses-A Prospective Analysis. [PDF]

Healthcare (Basel)
Niazi SK.
europepmc   +1 more source